Literature DB >> 21655674

Haemostatic profiles assessed by thromboelastography in patients with end-stage renal disease.

Andrew Darlington1, José Luis Ferreiro, Masafumi Ueno, Yoshi Suzuki, Bhaloo Desai, Piera Capranzano, Davide Capodanno, Antonio Tello-Montoliu, Theodore A Bass, Norris S Nahman, Dominick J Angiolillo.   

Abstract

Patients with end-stage renal disease (ESRD) have abnormalities in the cellular and plasmatic systems regulating blood homeostasis, which may contribute to their risk for thrombotic and bleeding complications. However, their relative contributions in this population are poorly understood. The aim of this study was to evaluate the distribution of enzymatic and cellular abnormalities in ESRD patients on haemodialysis as assessed by thromboelastography (TEG®). Whole blood samples were analysed by TEG in ESRD patients (n=70) and in a control group (n=70) of subjects with coronary artery disease. Profiles were constructed considering the maximum amplitude (MA), a marker of platelet function, and reaction time (R), a marker of thrombin generation, values. R values were higher in ESRD patients compared with the control group (8.2 ± 2.8 vs. 5.7 ± 1.9 minutes [min], p <0.0001), while there were no differences in MA (66.7 ± 8.1 vs. 66.2 ± 6.6 mm, p=0.562). Normal manufacturer defined coagulation (2-8 min) and aggregation (51-69 mm) parameters were present in 31% of ESRD patients compared with 56% of controls (p=0.006). A hypocoagulable status was observed in 42.9% of ESRD patients compared with 8.9% in the control group (p<0.0001). There were no differences in platelet function, which showed a hyperaggregable status in 41.4% versus 35.7% of cases (p=0.603). Abnormalities in both parameters were observed in 15.7% of ESRD patients versus 1.4% in the control group (p= 0.004), which were more common among older patients (p= 0.005). In conclusion, patients with ESRD have an elevated prevalence of abnormal haemostatic profiles, which may contribute to their elevated risk of bleeding and thrombotic complications.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21655674     DOI: 10.1160/TH10-12-0785

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  15 in total

1.  Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis.

Authors:  Adelina Hung; Guadalupe Garcia-Tsao
Journal:  Liver Int       Date:  2018-02-24       Impact factor: 5.828

2.  Microfluidics contrasted to thrombelastography: perplexities in defining hypercoagulability.

Authors:  Peter J Lawson; Hunter B Moore; Ernest E Moore; Mark E Gerich; Gregory R Stettler; Anirban Banerjee; Richard D Schulick; Trevor L Nydam
Journal:  J Surg Res       Date:  2018-06-08       Impact factor: 2.192

3.  Relationship between biomarkers and subsequent bleeding risk in ST-segment elevation myocardial infarction patients treated with paclitaxel-eluting stents: a HORIZONS-AMI substudy.

Authors:  Wouter J Kikkert; Bimmer E Claessen; Gregg W Stone; Roxana Mehran; Bernhard Witzenbichler; Bruce R Brodie; Jochen Wöhrle; Adam Witkowski; Giulio Guagliumi; Krzysztof Zmudka; José P S Henriques; Jan G P Tijssen; Elias A Sanidas; Vasiliki Chantziara; Ke Xu; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2013-02       Impact factor: 2.300

4.  The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial.

Authors:  Christina U Lorentz; Erik I Tucker; Norah G Verbout; Joseph J Shatzel; Sven R Olson; Brandon D Markway; Michael Wallisch; Martina Ralle; Monica T Hinds; Owen J T McCarty; David Gailani; Jeffrey I Weitz; András Gruber
Journal:  Blood       Date:  2021-12-02       Impact factor: 22.113

5.  Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.

Authors:  Yee Cheng Lau; Qinmei Xiong; Eduard Shantsila; Gregory Y H Lip; Andrew D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

6.  Thrombin-anti-thrombin levels and patency of arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: a prospective analysis.

Authors:  James A Milburn; Isobel Ford; Nicola J Mutch; Nicholas Fluck; Julie Brittenden
Journal:  PLoS One       Date:  2013-07-02       Impact factor: 3.240

7.  End-stage renal disease and outcome in a surgical intensive care unit.

Authors:  Mareike Apel; Vivian P L Maia; Mohamed Zeidan; Claudia Schinkoethe; Gunter Wolf; Konrad Reinhart; Yasser Sakr
Journal:  Crit Care       Date:  2013-12-23       Impact factor: 9.097

8.  Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.

Authors:  Y C Lau; Q Xiong; P Ranjit; G Y H Lip; A D Blann
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 9.  Antiplatelet Therapy in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions.

Authors:  Francesco Summaria; Maria B Giannico; Giovanni P Talarico; Roberto Patrizi
Journal:  Nephrourol Mon       Date:  2015-07-22

10.  Blood coagulation system in patients with chronic kidney disease: a prospective observational study.

Authors:  Meng-Jie Huang; Ri-Bao Wei; Yang Wang; Ting-Yu Su; Ping Di; Qing-Ping Li; Xi Yang; Ping Li; Xiang-Mei Chen
Journal:  BMJ Open       Date:  2017-06-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.